Prolyl oligopeptidase inhibitor suppresses the upregulation of ACSDKP in patients with acute myeloid leukemia

Cao,Haiwu; Zhao,Xiaohong; Lu,Shiyun; Wang,Zhi

doi:10.3892/etm.2018.6111

Prolyl oligopeptidase inhibitor suppresses the upregulation of ACSDKP in patients with acute myeloid leukemia

Authors:
- Haiwu Cao
- Xiaohong Zhao
- Shiyun Lu
- Zhi Wang
View Affiliations

Affiliations: Department of Hematology, Wuxi Second People's Hospital, Nanjing Medical University, Wuxi, Jiangsu 214002, P.R. China
Published online on: April 30, 2018 https://doi.org/10.3892/etm.2018.6111
Pages: 5431-5435

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the current study was to measure the expression of acetyl‑N‑Ser‑Asp‑Lys‑Pro (ACSDKP) in patients with acute myeloid leukemia (AML) and the effect of prolyl oligopeptidase inhibitor (POPi) on the bone marrow stromal cells of these patients. Serum and bone marrow stromal cell samples were collected from 33 patients with AML admitted to Wuxi Second People's Hospital, Nanjing Medical University between September 2011 and August 2016. ACSDKP levels were measured using a highly specific competitive enzyme immunoassay (EIA). Bone marrow stromal cells were treated with synthetic ACSDKP (10 µM/ml) or different concentrations of POPi S17092 (25, 50 and 100 µg/ml). Cells that received no treatment were used as control. An MTT assay was conducted to measure the proliferation of bone marrow stromal cells. The results demonstrated that serum levels of ACSDKP in patients with AML were significantly higher than those of controls (P<0.05). Following treatment with ACSDKP, cell proliferation was significantly increased compared with untreated cells (P<0.05). However, following treatment with different concentrations of POPi, the expression of ACSDKP was significantly decreased in a dose‑dependent manner (P<0.05). Furthermore, the proliferation of bone marrow stromal cells was also decreased in a dose‑dependent manner. Therefore, the present study demonstrated that ACSDKP levels were increased in the serum and bone marrow stromal cells of patients with AML and that ACSDKP promoted the proliferation of bone marrow stromal cells of these patients, which was inhibited by POPi. These results may identify a novel target for the treatment of AML.

View Figures

View References

1	Stelljes M, Beelen DW, Braess J, Sauerland MC, Heinecke A, Berning B, Kolb HJ, Holler E, Schwerdtfeger R, Arnold R, et al: Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: Landmark analysis from a single prospective multicenter trial. Haematologica. 96:972–979. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
4	Medeiros BC, Othus M, Estey EH, Fang M and Appelbaum FR: Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Haematologica. 97:1401–1404. 2012. View Article : Google Scholar : PubMed/NCBI
5	Tsai RJ, Luckhaupt SE, Schumacher P, Cress RD, Deapen DM and Calvert GM: Acute myeloid leukemia risk by industry and occupation. Leuk Lymphoma. 55:2584–2591. 2014. View Article : Google Scholar : PubMed/NCBI
6	Wang ML and Bailey NG: Acute myeloid leukemia genetics: Risk stratification and implications. Arch Pathol Lab Med. 139:1215–1223. 2015. View Article : Google Scholar : PubMed/NCBI
7	Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, et al: Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 374:2209–2221. 2016. View Article : Google Scholar : PubMed/NCBI
8	The Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 507:315–322. 2014. View Article : Google Scholar : PubMed/NCBI
9	Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, Kennedy JA, Schimmer AD, Schuh AC, Yee KW, et al: Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 506:328–333. 2014. View Article : Google Scholar : PubMed/NCBI
10	Döhner H, Weisdorf DJ and Bloomfield CD: Acute myeloid leukemia. N Engl J Med. 373:1136–1152. 2015. View Article : Google Scholar : PubMed/NCBI
11	Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, Chen K, Shin M, Wall DM, Hönemann D, et al: Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 21:2122–2129. 2013. View Article : Google Scholar : PubMed/NCBI
12	Ding G, Zhang Z, Chopp M, Li L, Zhang L, Li Q, Wei M and Jiang Q: MRI evaluation of BBB disruption after adjuvant AcSDKP treatment of stroke with tPA in rat. Neuroscience. 271:1–8. 2014. View Article : Google Scholar : PubMed/NCBI
13	Huang WQ, Wang BH and Wang QR: Thymosin beta4 and AcSDKP inhibit the proliferation of HL-60 cells and induce their differentiation and apoptosis. Cell Biol Int. 30:514–520. 2006. View Article : Google Scholar : PubMed/NCBI
14	Liu JM, Lawrence F, Kovacevic M, Bignon J, Papadimitriou E, Lallemand JY, Katsoris P, Potier P, Fromes Y and Wdzieczak-Bakala J: The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo. Blood. 101:3014–3020. 2003. View Article : Google Scholar : PubMed/NCBI
15	Xu H, Yang F, Sun Y, Yuan Y, Cheng H, Wei Z, Li S, Cheng T, Brann D and Wang R: A new antifibrotic target of Ac-SDKP: Inhibition of myofibroblast differentiation in rat lung with silicosis. PloS One. 7:e403012012. View Article : Google Scholar : PubMed/NCBI
16	Kusinski M, Wdzieczak-Bakala J, Liu JM, Bignon J and Kuzdak K: Acsdkp: A new potential marker of malignancy of the thyroid gland. Langenbecks Arch Surg. 391:9–12. 2006. View Article : Google Scholar : PubMed/NCBI
17	Liu JM, Garcia-Alvarez MC, Bignon J, Kusinski M, Kuzdak K, Riches A and Wdzieczak-Bakala J: Overexpression of the natural tetrapeptide acetyl-N-ser-asp-lys-pro derived from thymosin beta4 in neoplastic diseases. Ann N Y Acad Sci. 1194:53–59. 2010. View Article : Google Scholar : PubMed/NCBI
18	Liu JM, Kusinski M, Ilic V, Bignon J, Hajem N, Komorowski J, Kuzdak K, Stepien H and Wdzieczak-Bakala J: Overexpression of the angiogenic tetrapeptide acsdkp in human malignant tumors. Anticancer Res. 28:2813–2817. 2008.PubMed/NCBI
19	Liozon E, Volkov L, Comte L, Trimoreau F, Pradelles P, Bordessoule D, Frindel E and Praloran V: Acsdkp serum concentrations vary during chemotherapy in patients with acute myeloid leukaemia. Br J Haematol. 89:917–920. 1995. View Article : Google Scholar : PubMed/NCBI
20	Hu P, Li B, Zhang W, Li Y, Li G, Jiang X, Wdzieczak-Bakala J and Liu J: AcSDKP regulates cell proliferation through the PI3KCA/Akt signaling pathway. PloS One. 8:e793212013. View Article : Google Scholar : PubMed/NCBI
21	Vardiman JW, Harris NL and Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 100:2292–2302. 2002. View Article : Google Scholar : PubMed/NCBI
22	Drexler HG: Classification of acute myeloid leukemias-a comparison of FAB and immunophenotyping. Leukemia. 1:697–705. 1987.PubMed/NCBI
23	Lv H, Che T, Tang X, Liu L and Cheng J: Puerarin enhances proliferation and osteoblastic differentiation of human bone marrow stromal cells via a nitric oxide/cyclic guanosine monophosphate signaling pathway. Mol Med Rep. 12:2283–2290. 2015. View Article : Google Scholar : PubMed/NCBI
24	Juopperi TA, Bienzle D, Bernreuter DC, Vernau W, Thrall MA and McManus PM: Prognostic markers for myeloid neoplasms: A comparative review of the literature and goals for future investigation. Vet Pathol. 48:182–197. 2011. View Article : Google Scholar : PubMed/NCBI
25	Cîrstea M, Coliță A, Ionescu B, Ghiaur A, Vasilescu D, Dobrea C, Jardan C, Dragomir M, Gheorghe A, Várady Z and Lupu AR: Therapy-related myelodysplastic syndrome after successful treatment of acute promyelocytic leukemia: Case report and literature review. Revista Romana De Medicina De Laborator. 25:165–179. 2017. View Article : Google Scholar
26	Frindel E, Masse A, Pradelles P, Volkov L and Rigaud M: Correlation of endogenous acetyl-ser-asp-lys-pro plasma levels in mice and the kinetics of pluripotent hemopoietic stem cells entry into the cycle after cytosine arabinoside treatment: Fundamental and clinical aspects. Leukemia. 6:599–601. 1992.PubMed/NCBI